Patents by Inventor Sabine Imhof-Jung

Sabine Imhof-Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20180222993
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20180222992
    Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 9, 2018
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20180222980
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: January 24, 2018
    Publication date: August 9, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • BISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20180079805
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 24, 2017
    Publication date: March 22, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Sabine IMHOF-JUNG, Christian KLEIN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Juergen Michael SCHANZER
  • Bispecific T cell activating antigen binding molecules
    Patent number: 9914776
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 13, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170369566
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 23, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • MULTISPECIFIC ANTIBODIES
    Publication number: 20170349669
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: May 15, 2017
    Publication date: December 7, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: SABINE IMHOF-JUNG, CHRISTIAN KLEIN, STEFAN KLOSTERMANN, JOERG THOMAS REGULA, WOLFGANG SCHAEFER
  • BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170240626
    Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: October 4, 2016
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 9708396
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170190783
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: July 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christianne Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170174786
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: June 22, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Pablo Umana, Sylvia Herter, Christiane Neumann
  • Bispecific antigen binding proteins
    Patent number: 9676845
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: June 13, 2017
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
  • TETRAVALENT MULTISPECIFIC ANTIBODIES
    Publication number: 20170145116
    Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 25, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG THOMAS REGULA, STEFAN SEEBER, WOLFGANG SCHAEFER, SABINE IMHOF-JUNG, MICHAEL MOLHOJ, MAXIMILIANE KOENIG, PETER BRUENKER, CHRISTIAN KLEIN
  • MULTISPECIFIC ANTIBODIES
    Publication number: 20170129962
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 11, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG THOMAS REGULA, WOLFGANG SCHAEFER, MICHAEL MOLHOJ, SABINE IMHOF-JUNG, CHRISTIAN KLEIN
  • Bispecific T cell activating antigen binding molecules
    Publication number: 20170114146
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Tanja Fauti, Charles Dumontet, Pablo Umana, Marina Bacac, Anne Freimoser-Grundschober
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170096495
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Thomas HOFER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Tapan NAYAK, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170096485
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Gerhard NIEDERFELLNER, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA
  • MODIFIED PSEUDOMONAS EXOTOXIN A
    Publication number: 20170051072
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Application
    Filed: June 23, 2016
    Publication date: February 23, 2017
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
  • Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
    Publication number: 20170008949
    Abstract: Herein is reported the use of a conjugate of a subunit of a multi-subunit structure and one biologically active entity for targeted delivery of the biologically active entity to the multi-subunit structure.
    Type: Application
    Filed: June 9, 2016
    Publication date: January 12, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Marcel Gubler, Sabine Imhof-Jung
  • Modified exotoxin A
    Patent number: 9388222
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 12, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Hoffman-La Roche Inc.
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Guy Georges